| Literature DB >> 21998649 |
Gisela Sugranyes1, Marinos Kyriakopoulos, Richard Corrigall, Eric Taylor, Sophia Frangou.
Abstract
CONTEXT: Impaired social cognition is a cardinal feature of Autism Spectrum Disorders (ASD) and Schizophrenia (SZ). However, the functional neuroanatomy of social cognition in either disorder remains unclear due to variability in primary literature. Additionally, it is not known whether deficits in ASD and SZ arise from similar or disease-specific disruption of the social cognition network.Entities:
Mesh:
Year: 2011 PMID: 21998649 PMCID: PMC3187762 DOI: 10.1371/journal.pone.0025322
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Details of studies included in the meta-analysis for facial emotion recognition tasks.
| Reference | Patients/Controls | Task | Contrast used | Matching |
|
| ||||
| Hall et al, 2010 | 12/12 | Implicit | Anxious>Neutral faces | Gender, age, non-verbal IQ |
| Monk et al, 2010 | 12/12 | Implicit | Sad>Neutral faces | Gender, age, handedness, IQ |
| Deeley et al, 2007 | 9/9 | Implicit | Fear>Neutral faces | Gender, age, verbal IQ |
| Ashwin et al, 2007 | 13/13 | Implicit | Fear>Scrambled faces | Gender, age, handedness |
| Critchley et al, 2000 | 9/9 | Implicit and Explicit | Angry>Neutral faces | Gender, age, IQ |
|
| ||||
| Rauch et al, 2010 | 12/12 | Implicit | Sad>Neutral faces | Age, handedness |
| Dowd et al, 2010 | 32/40 | Explicit valence rating task | Negative>Neutral | Gender, age, handedness, parental education |
| Seiferth et al, 2009 | 12/12 | Explicit labeling task | Fearful>Neutral faces | Gender, age, handedness, parental education |
| Reske et al, 2009 | 18/18 | Emotion discrimination task | Sad>Neutral faces | Gender, age, parental education |
| Michalopoulou et al, 2008 | 11/9 | Implicit | Fearful>Neutral faces | Age, handedness, education |
| Hall et al, 2008 | 19/24 | Implicit | Fearful>Neutral faces | Gender, age, IQ |
| Williams et al, 2007 | 13/13 | Implicit | Fearful>Neutral faces | Gender, age, handedness, IQ |
| Williams et al, 2007 | 14/13 | Implicit | Fearful>Neutral faces | Gender, age, handedness, IQ |
| Gur et al, 2007 | 16/17 | Emotion discrimination task | Fearful>Neutral faces | Gender, handedness, parental education |
| Das et al, 2007 | 14/14 | Implicit and Explicit | Fearful>Neutral | Gender, age, handedness |
| Surguladze et al, 2006 | 15/11 | Implicit | Fearful>Neutral faces | Gender, age, handedness, education |
| Holt et al, 2006 | 15/16 | Implicit | Fearful>Neutral | Gender, age, education, parental education |
| Kosaka et al, 2002 | 12/12 | Emotional intensity judgment task | Negative>Neutral faces | Gender, age, handedness |
Clinical description of patients with Autism Spectrum Disorders included in facial emotion recognition studies.
| Reference | Mean age (SD) Patients/Controls | Gender (% male) Patients/Controls | Symptom Scales Mean score (SD) | Diagnosis/Recruitment/Illness Duration | Medication Dose (mg): mean (SD)* |
| Hall et al, 2010 | 31.8/32 | 100%/100% | ADOS (Communication): 5.22 (1.39) ADOS (Social interaction): 10.33 (2.73) | HFA, Asperger, PDD-NOS | No information provided |
| Monk et al, 2010 | 26/27 | 100%/100% | ADI-R/ADOS | HFA (n = 7), Asperger(n = 2), PDD-NOS (n = 3) | SSRI (n = 5), stimulants (n = 4), NLP (n = 2), TCA (n = 1),BZD (n = 1) |
| Deeley et al, 2007 | 34 (10)/27(5) | 100%/100% | ADI-R/ADOS | Asperger | Unmedicated |
| Ashwin et al, 2007 | 31/25 | 100%/100% | Autism Quotient: 35.6 (6.3) | HFA/Asperger | Unmedicated |
| Critchley et al, 2000 | 37(7)/27(7) | 100%/100% | ADI-R | HFA (n = 2), Asperger (n = 7) | No information provided |
ADI-R = Autism Diagnostic Interview-Revised [77]; ADOS = Autism Diagnostic Observation Schedule [78]; BZD = benzodiazepine; HFA = High Functioning Autism; PDD-NOS = Pervasive Developmental Disorder Not Otherwise Specified; NLP = neuroleptics; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.
Clinical description of patients with Schizophrenia included in facial emotion recognition studies.
| Reference | Age Mean (SD) Patients/Controls | Gender (% male) Patients/Controls | Symptom Scales Mean score (SD) | Diagnosis/Recruitment/Illness Duration | Medication Dose (mg): mean (SD)* |
| Rauch et al, 2010 | 27.7 (7.5)/26.9 (6.1) | 58.3%/75% | PANSS Positive: 14.4 (3.1); PANSS Negative: 18.9 (5.2); PANSS General: 34.9 (5.9) | Inpatients | NLP: 902.1 (603.2) |
| Dowd et al, 2010 | 36.25 (10.85)/36.8 (8.99) | 65.2%/65% | SAPS: 1.83 (.93); SANS: 1.81 (1.37) | Schizophrenia/schizoaffective disorder outpatients. Duration of illness: 17.73 years (11.25). | NLP: 452.20 (369.60) |
| Seiferth et al, 2009 | 17.8 (1.4)/17.9 (1.5) | 100%/100% | PANSS Positive: 16.2 (8.1); PANSS Negative: 13.3 (8.9) | Early onset schizophrenia, Mean duration of illness: 38 weeks | NLP: 231 (111) |
| Reske et al, 2009 | 31.94 (6.41)/31.94 (6.03) | 55.5%/55.5% | PANSS Positive: 8 (1.14); PANSS Negative: 13.61 (4.47); PANSS total: 23.11 (3.94) | First episode psychosis, inpatients | Double blind treatment with haloperidol (mean dose 2.56mg/d) or risperidone (mean dose 2.23 mg/d) for 6 to 8 weeks |
| Michalopoulou et al, 2008 | 35 (9)/32 (6) | 81.2%/55.5% | PANSS positive: 16 (6.72); PANSS negative: 13.91 (5.54); PANSS total: 58.91 (17.72) | Outpatients. Duration of illness: 12 years (9) | NLP: 523 (455) |
| Hall et al, 2008 | 37.7 (8.4)/35.1 (9.7) | 63.15%/66.6% | PANSS Positive: 12.3 (4.5) | Inpatient and outpatients. OPCRIT criteria | NLP: 496 (377) |
| Williams et al, 2007 | 26.9 (9.1)/25.1 (8.1) | 61.5%/63% | PANSS positive (delusions):5.2 (1.2); (excitement): 3.7 (0.6) | Duration of illness: 5.6 years (4.6) | NLP: 375.1 (290.6) |
| Williams et al, 2007 | 27.8 (10.4)/25.1 (8.1) | 64.3%/63% | PANSS Positive (delusions): 2.1 (1.1); 1.6 (0.8) | Duration of illness: 5.6 years (4.6) | NLP: 339.3 (240.3) |
| Gur et al, 2007 | 30.1 (6.5)/25 (3.9) | 75%/70.6% | SAPS: 1.4 (0.6); SANS: 1.3 (0.9) | Duration of illness: 9.6 years (7.1), hospitalizations: 3.6 (4.1) | Untreated (n = 1); First generation NLP (542 mg/day (292)) (n = 2); Olanzapine (18.2 mg/day (2.8)) (n = 11); Both (n = 2). |
| Das et al, 2007 | 20.4 (3.3)/23.1 (5.9) | 100%/100% | PANSS Positive: 16.07 (7.24); PANSS Negative: 21.14 (7.9) | First episode psychosis, Duration of illness: 1.21 years (1.2) | Unmedicated (n = 5); Atypical NLP, 393.4 (213.2) (n = 9) |
| Surguladze et al, 2006 | 43.1 (8.8)/36.8 (10.6) | 100%/100% | SAPS: 25.1 (23.9); SANS: 27.9 (14.6) | Duration of illness: 19.9 years (10.5), hospitalizations 5.7 (5.4) | NLP: 487.1 (range: 100–1200 mg/day) |
| Holt et al, 2006 | 47.7 (7.1)/48.2 (9.6) | 100%/100% | PANSS Positive and Negative Syndrome Scale: 59.8 (10.3) | Outpatients. Duration of illness: 21.6 years (9.6) | NLP: 424.5 (268.8) |
| Kosaka et al, 2002 | 26 (4.5)/24.4 (2.4) | 50%/50% | PANSS Positive: 11-3 (4.6); PANSS Negative: 16.3 (4.5); PANSS General: 28.8 (7.3) | Outpatients and inpatients. Duration of illness: 3.8 years (3.5) | NLP: 322.0 mg (264.1) Unmedicated (n = 2) |
Unless otherwise specified, neuroleptic dose expressed in chlorpromazine equivalents; NLP = neuroleptics; PANSS = Positive and Negative Syndrome Scale for Schizophrenia [79]; SAPS = Scale for the Assessment of Positive Symptoms [80]; SANS = Scale for the Assessment of Negative Symptoms [81];
Activation likelihood estimation results for facial emotion recognition in patients with schizophrenia or autism spectrum disorders compared to healthy controls.
| Brain region | Gyrus | BA | Laterality | Site of maximum ALE | Volume (mm3) | Maximum ALE value | ||
| x | y | z | ||||||
|
| ||||||||
|
| ||||||||
| Temporal | Superior Temporal | 42/22 | Left | −56 | −24 | 6 | 424 | 0.01067 |
|
| ||||||||
| Parietal | Postcentral | 3 | Left | −40 | −20 | 50 | 320 | 0.01286 |
|
| ||||||||
|
| ||||||||
| No significant clusters | - | - | - | - | - | - | - | - |
|
| ||||||||
| Frontal | Inferior Frontal | 47 | Right | 36 | 18 | −18 | 80 | 0.09672 |
| Limbic | Posterior Cingulate | 23 | Right | 4 | −26 | 24 | 80 | 0.00872 |
| Limbic | Amygdala | Left | −22 | −2 | −12 | 96 | 0.01012 | |
| Occipitopemporal | Fusiform | 19 | Right | 28 | −74 | −10 | 200 | 0.01012 |
| Thalamus | Dorsomedial | Left | −2 | −12 | 12 | 208 | 0.01018 | |
*x = sagittal, y = coronal, z = axial coordinates according to Talairach and Tournoux; BA = Brodmann Area; ALE = Activation Likelihood Estimation, p<0.05 False Rate Discovery corrected for multiple comparisons. SZ = Schizophrenia, ASD = Autism Spectrum Disorders, HC = Healthy Controls.
Figure 1Activation likelihood estimation maps comparing autism spectrum disorder subjects with healthy controls.
Clusters of relative underactivation or overactivation in ASD are shown in blue and red respectively; numbers represent the sagittal (x), coronal (y) and axial (z) coordinates of each slice in Talairach space. p<0.05 False Rate Discovery corrected for multiple comparisons. ASD = Autism Spectrum Disorders, HC = Healthy Controls.
Figure 2Activation likelihood estimation maps comparing schizophrenia patients with healthy controls.
Clusters of relative underactivation or overactivation in SZ are shown in blue and red respectively; numbers represent the sagittal (x), coronal (y) and axial (z) coordinates of each slice in Talairach space. p<0.05 False Rate Discovery corrected for multiple comparisons. SZ = Schizophrenia, HC = Healthy Controls.
Activation likelihood estimation results for facial emotion recognition comparison of schizophrenia and autism spectrum disorders.
| Brain region | Gyrus | BA | Laterality | Site of maximum ALE | Volume (mm3) | Maximum ALE value | ||
| x | y | z | ||||||
|
| ||||||||
| Limbic | Anterior Cingulate | 24 | Left | 0 | 26 | 20 | 392 | 0.00652 |
| Limbic | Anterior Cingulate | 32 | Right | 10 | 34 | 20 | 376 | 0.00652 |
| Limbic | Posterior Cingulate | 30 | Left | −20 | −62 | 4 | 320 | 0.00645 |
| Temporal | Superior Temporal | 42/22 | Left | −56 | −24 | 6 | 1824 | 0.00884 |
| Temporal | Superior Temporal | 22 | Right | 40 | −48 | 14 | 432 | 0.00663 |
|
| ||||||||
| Frontal | Inferior Frontal | 47 | Left | −36 | 28 | 2 | 392 | 0.00646 |
| Limbic | Parahippocampus | 28 | Left | −22 | −22 | −10 | 392 | 0.00629 |
| Parietal | Inferior Parietal | 40 | Left | −50 | −44 | −40 | 360 | 0.00647 |
| Occipital | Inferior Occipital | 18 | Right | 32 | −84 | −4 | 304 | 0.00646 |
| Cerebellum | Culmen | - | Left | −30 | −46 | −20 | 352 | 0.00654 |
| Cerebellum | Culmen | - | Right | 32 | −44 | −18 | 304 | 0.00639 |
| Cerebellum | Declive | - | Left | −30 | −76 | −20 | 384 | 0.00651 |
| Cerebellum | Declive | - | Right | 26 | 68 | −14 | 376 | 0.00651 |
x = sagittal, y = coronal, z = axial coordinates according to Talairach and Tournoux. BA = Brodmann Area; ALE = Activation Likelihood Estimation, p<0.05 False Rate Discovery corrected for multiple comparisons.
Figure 3Activation likelihood estimation maps comparing autism spectrum disorder with schizophrenia patients.
Clusters of relative overactivation and underactivation in ASD are shown in green and yellow respectively; numbers represent the sagittal (x), coronal (y) and axial (z) coordinates of each slice in Talairach space. p<0.05 False Rate Discovery corrected for multiple comparisons. ASD = Autism Spectrum Disorders, SZ = Schizophrenia.
Details of studies included in the meta-analysis for theory of mind tasks.
| Reference | Patients/Controls | Task | Contrast used | Matching |
|
| ||||
| Lombardo et al, 2010 | 23/23 | Judgment of self or other physical or mental states | Other mentalising>Self mentalising | Gender, age, IQ, handedness |
| Uddin et al, 2008 | 8/12 | Self face recognition paradigm | Self>Rest | Gender, age, IQ, handedness |
| Wang et al, 2007 | 18/18 | Judgment of irony | Irony>No Irony conditions | Gender, age, handedness |
| Dapretto et al, 2006 | 10/10 | Imitation of facial expressions | Imitation of facial expressions>Passive observation | Gender, age, IQ |
| Williams et al, 2006 | 16/15 | Imitation of facial expression | Imitation>Observation of animated facial expressions | Gender, age, IQ, handedness |
| Pelphrey et al, 2005 | 10/9 | Judgment of congruency of eye gaze shift | Incongruent>Congruent gaze shift | Gender, age, IQ, handedness |
| Baron-Cohen et al, 1999 | 6/12 | Judgment of mental states from pictures of eyes | Judgment of mental state>Judgment of gender | Gender, age, IQ, handedness, socioeconomic status, education |
|
| ||||
| Park et al, 2011 | 14/15 | Listening and viewing of self or other referential vignettes | Other referential>Neutral | Gender, age, handedness, education |
| Lee et al, 2010 | 15/18 | Empathic story completion task | Empathic>Factual | Gender, age, verbal IQ, handedness, education |
| Holt et al, 2010 | 17/18 | Self or other referential affect labeling, and perceptual processing of adjectives | Other referential>Perceptual processing | Gender, age, IQ, handedness, ethnicity, parental socio-economic status |
| Walter et al, 2009 | 12/12 | Intentional story completion task | Intentional>Factual causality | Gender, age, handedness, education |
| Benedetti et al, 2009 | 24/20 | Judgment of intentions or empathy | Intention and empathy>Physical causality | Gender, age, handedness |
| Dollfus et al, 2008 | 23/23 | Judgment of corruption | Judgment of corruption>Factual | Gender, age, handedness, education |
| Brune et al, 2008 | 9/13 | Judgments of cooperation or deceit | Mentalising judgment>Factual judgment | Gender, age, handedness |
| Lee et al, 2006 | 14/14 | Judgment of empathy | Empathic>Factual judgments | Gender, age, handedness, IQ |
| Russell et al, 2000 | 5/7 | Judgment of mental states from pictures of eyes | Judgment of mental state>Judgment of gender | Gender, age, handedness, education |
Clinical description of patients with Autism Spectrum Disorders included in theory of mind studies.
| Reference | Mean age (SD) Patients/Controls | Gender (% male) Patients/Controls | Symptom Scales Mean scores (SD) | Diagnosis/Recruitment/Illness Duration | Medication Dose (mg): mean (SD)* |
| Lombardo et al, 2010 | 27.97 (6.10)/26.59 (7.04) | 100% | ADI-R: (Social): 18.07 (5.07), (Communication): 15.17 (4.24), (Rep): 5.97 (2.76) AQ (ASD): 32.59 (8.20); AQ (HC): 15.24 (6.89) | Asperger Syndrome | No information provided |
| Uddin et al, 2008 | 13.19 (2.61)/12.23 (2.1) | 100% | ADOS, ADI-R | HFA | None |
| Wang et al, 2007 | 11.8 (2.9)/11.8 (1.9) | 100% | ADOS, ADI-R, Social Responsiveness Scale | HFA | Medicated (SSRIs, stimulants, atypical NLP) (n = 7) |
| Dapretto et al, 2006 | 12.05 (2.5)/12.38 (2.2) | 100% | ADOS (Social) 8.5 (3.0); ADI (Social): 20.3 (4.9) | HFA | No information provided |
| Williams et al, 2006 | 15.4 (2.24)/15.5 (1.60) | 100%/100% | ADOS, ADI-R | HFA | Methylphenidate (n = 2), clonidine, dexamphetamine and melatonin (n = 1) |
| Pelphrey et al, 2005 | 23.2 (9.9)/23.4 (5.8) | 90%/89% | ADOS, ADI-R | HFA | No information provided |
| Baron-Cohen et al, 1999 | 26.3 (2.1)/25.5 (2.8) | 67%/50% | DSM-IV, ICD-10 | HFA | No information provided |
ADI-R = Autism Diagnostic Interview-Revised [77]; ADOS = Autism Diagnostic Observation Schedule [78]; AQ = Autism Spectrum Quotient [96]; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; HFA = High Functioning Autism; ICD-10 = International Classification of Diseases, 10th Revision; NLP = neuroleptics; SSRI = selective serotonin reuptake inhibitor.
Clinical description of patients with Schizophrenia included in theory of mind studies.
| Reference | Mean age (SD) Patients/Controls | Gender (% male) Patients/Controls | Symptom Scales Mean scores (SD) | Diagnosis/Recruitment/Illness Duration | Medication Dose (mg): mean (SD)* |
| Lee et al, 2010 | 26.0 (4.3)/25.8 (2.2) | 47%/50% | PANSS Positive = 13.1 (5.1); PANSS Negative = 15.4 (4.1); PANSS Total = 64.4 (11.0) | Stable outpatients; Duration of illness: 4.6 years (3.4) | 422.1 (23.7); Olanzapine (n = 4), aripirazole (n = 4), risperidone (n = 2), amisulpride (n = 2), clozapine (n = 1), perphenacine (n = 1), ziprasidone (n = 1) |
| Holt et al, 2010 | 35.9 (13.7)/40.0 (12.5) | 65%/67% | PANSS Positive = 11.7 (3.6); PANSS Negative = 11.4 (3.2); PANSS General = 24.2 (5.2); PANSS Total = 47.3 (10.0) | Stable outpatients; Duration of illness: 13.2 years (12.8) | NLP 374.1 (364.0) |
| Walter et al, 2009 | 29.5 (6.9)/24.7 (2.6) | 50%/50% | PANSS Positive = 17.75 (5.06); PANSS Negative = 19.41 (3.96); PANSS Total = 73.75 (11.02); Brief Psychiatric Rating Scale = 47.18 (10.6) | Inpatients; Duration of illness: 6.3 years (5.2) | No information provided |
| Benedetti et al, 2009 | 37.2 (10.23)/35.1 (9.95) | 58%/5% | PANSS Positive = 16 (4.58); PANSS Negative = 21.66 (5.42); PANSS Total = 72.57 (14.49) | Stable outpatients; SZ subtypes: undifferentiated (n = 9), paranoid (n = 13), disorganized (n = 2); Duration of illness: 12.7 years (6.96) | 357.81 (256.17). Monotherapy, stable doses for prior 3 months. Clozapine (n = 9), risperidone (n = 11), aripiprazole (n = 2), haloperidol (n = 2). |
| Dollfus et al, 2008 | 29.9 (7.9)/30.0 (8.6) | 78%/78% | PANSS Positive = 11.7 (4.5); PANSS Negative = 13.1 (5.0); PANSS Total = 49.5 (14.8) | Stable outpatients;. Duration of illness: 7.6 years (7.2) | NLP: 315.5 (256.2) |
| Brune et al, 2008 | 27.89(6.6)/26.46(5.30) | 33%/31% | PANSS Positive = 16.67 (5.75); PANSS Negative = 15.67 (8.87) | First Episode (n = 6), recurrent episodes (n = 3); Duration of illness: 3.0 years (4.23) | NLP:244.44 (173) |
| Lee et al, 2006 | 31.7(7.3)/30.5(8.8) | 93%/93% | SAPS = 2.4 (2.0); SANS = 5.4 (3.0) | Outpatients; Duration of illness: 9.8 years (5.4) | 406.4 (205.6); Clozapine (n = 5), olanzapine (n = 4), risperidone (n = 1), typical NLP (n = 4). |
| Russell et al, 2000 | 36 (9)/40(11) | 100%/100% | DSM-IV criteria | Duration of illness: 13 years (7) | Receiving NLP |
Unless otherwise specified neuroleptic dose expressed in chlorpromazine equivalents; duration of illness is presented as mean (standard deviation); DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; NLP = neuroleptics; PANSS = Positive and Negative Syndrome Scale for Schizophrenia [79]; SAPS = Scale for the Assessment of Positive Symptoms [80]; SANS = Scale for the Assessment of Negative Symptoms [81].
Activation likelihood estimation results for theory of mind in patients with schizophrenia or autism spectrum disorders compared to healthy controls.
| Brain Region | Gyrus | BA | Laterality | Site of maximum ALE | Volume (mm3) | Maximum ALE value | ||
| x | y | z | ||||||
|
| ||||||||
|
| ||||||||
| No significant clusters | - | - | - | - | - | - | - | - |
|
| ||||||||
| Frontal | Medial Frontal | 9/10 | Left | −2 | 52 | 28 | 176 | 0.01022 |
| Frontal | Precentral | 44 | Right | 54 | 8 | 8 | 96 | 0.00939 |
| Limbic | Anterior Cingulate | 24 | Left | −2 | −2 | 40 | 248 | 0.01126 |
| Limbic | Amygdala | Left | −22 | −8 | −8 | 272 | 0.01309 | |
| Temporal | Middle Temporal | 21 | Left | −56 | −36 | 0 | 176 | 0.01038 |
| Parietal | Inferior Parietal | 40 | Left | −38 | −32 | 48 | 344 | 0.01117 |
|
| ||||||||
|
| ||||||||
| Parietal | Paracentral Lobule | 5 | Right | 2 | −38 | 54 | 176 | 0.00946 |
| Limbic | Posterior Cingulate | 23 | Left | 0 | −16 | 24 | 88 | 0.00971 |
|
| ||||||||
| Frontal | Medial Frontal | 9/10 | Left | −6 | 50 | 26 | 64 | 0.00922 |
| Limbic | Posterior Cingulate | 23 | Right | 10 | −32 | 22 | 232 | 0.01019 |
| Temporal | Middle Temporal | 22 | Left | −58 | −36 | 4 | 120 | 0.00978 |
| Thalamus | Pulvinar | Left | −6 | −32 | 8 | 272 | 0.01134 | |
x = sagittal, y = coronal, z = axial coordinates according to Talairach and Tournoux; BA = Brodmann Area; ALE = Activation Likelihood Estimation, p<0.05 False Rate Discovery corrected for multiple comparisons.
Activation likelihood estimation results for theory of mind tasks comparison of schizophrenia and autism spectrum disorders.
| Brain region | Gyrus | BA | Laterality | Site of maximum ALE | Volume (mm3) | Maximum ALE value | ||
| x | y | z | ||||||
|
| ||||||||
| Limbic | Insula | 13 | Right | 32 | −2 | 12 | 200 | 0.00636 |
|
| ||||||||
| Frontal | Medial Frontal | 10 | Right | 8 | 60 | 4 | 168 | 0.00627 |
| Frontal | Paracentral Lobule | 5 | Left | 0 | −36 | 52 | 656 | 0.00784 |
| Limbic | Posterior Cingulate | 23 | Left | 0 | −16 | 24 | 624 | 0.00706 |
| Limbic | Posterior Cingulate | 31 | Left | −6 | −30 | 34 | 200 | 0.00665 |
x = sagittal, y = coronal, z = axial coordinates according to Talairach and Tournoux; BA = Brodmann Area; ALE = Activation Likelihood Estimation, p<0.05 False Rate Discovery corrected for multiple comparisons.